These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15060437)

  • 21. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
    Furfine ES; Baker CT; Hale MR; Reynolds DJ; Salisbury JA; Searle AD; Studenberg SD; Todd D; Tung RD; Spaltenstein A
    Antimicrob Agents Chemother; 2004 Mar; 48(3):791-8. PubMed ID: 14982766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
    Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
    Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
    Wood R; Eron J; Arasteh K; Teofilo E; Trepo C; Livrozet JM; Yeo J; Millard J; Wire MB; Naderer OJ
    Clin Infect Dis; 2004 Aug; 39(4):591-4. PubMed ID: 15356829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM; Gibiansky L; Wire MB
    J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB; Baker KL; Jones LS; Shelton MJ; Lou Y; Thomas GJ; Berrey MM
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
    van der Lee MJ; Blenke AA; Rongen GA; Verwey-van Wissen CP; Koopmans PP; Pharo C; Burger DM
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4098-104. PubMed ID: 17846135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz.
    Usami Y; Oki T; Nakai M; Sagisaka M; Kaneda T
    Chem Pharm Bull (Tokyo); 2003 Jun; 51(6):715-8. PubMed ID: 12808252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
    Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.
    Huang F; Drda K; MacGregor TR; Scherer J; Rowland L; Nguyen T; Ballow C; Castles M; Robinson P
    Antimicrob Agents Chemother; 2009 Jan; 53(1):95-103. PubMed ID: 18955519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
    HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.